Business Context and Reporting Period
This Form 8-K was filed by EyeGate Pharmaceuticals, Inc. (trading symbol: EYEG) on May 13, 2019. The report addresses a critical corporate governance event regarding the company's listing status on The Nasdaq Capital Market. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding a specific event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Events
- Nasdaq Delisting Notice: On March 19, 2019, Nasdaq notified the company of non-compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"), which requires a minimum closing bid price of $1.00 per share.
- Appeal Process: The company requested a hearing before the Nasdaq Hearings Panel, which stayed the scheduled delisting date of March 28, 2019. The hearing took place on May 2, 2019.
- Panel Decision: On May 13, 2019, the Panel granted the company's request for continued listing.
- Extension Terms: The listing extension is valid through September 16, 2019. Continued listing is conditional upon the company regaining compliance with the Bid Price Rule by this date.
Outlook, Risks, and Contingencies
The company faces a significant contingency: if it fails to regain compliance with the $1.00 minimum bid price requirement by September 16, 2019, or if significant events occur during the extension period prompting a reconsideration, Nasdaq will delist the company's common stock. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks described in the company's Form 10-K filed on March 1, 2019.
Investor Verification Checklist
- Verify the current closing bid price of EYEG stock to assess progress toward the $1.00 compliance threshold.
- Monitor the company's press releases and filings for any updates on capital raising activities or reverse stock splits intended to meet the bid price requirement.
- Review the Form 10-K filed on March 1, 2019, for detailed risk factors related to the company's financial position and operational challenges.
- Confirm the exact deadline of September 16, 2019, for regaining compliance to avoid delisting.